‘Cheers’ Actress Kirstie Alley Dies Shortly After Receiving Colon Cancer Diagnosis

Article

Actress Kirstie Alley, who is known for roles in “Cheers,” “Look Who’s Talking’” and other television shows and movies, died a short time after receiving a colon cancer diagnosis, according to a family statement.

Actress Kirstie Alley died from cancer

Kirstie Alley, who starrred in the TV show, "Cheers," among others, died after a cancer diagnosis that was "only recently discovered," according to a statement from her family.

Credit: NBCUniversal via Getty Images.

Actress Kirstie Alley, who stared in “Cheers” and “Drop Dead Gorgeous,” died shortly after receiving a diagnosis of cancer, according to a statement from her family.

The two-time Emmy-winning actress was 71 and died from colon cancer, according to a statement shared with "People" magazine.

“We are sad to inform you that our incredible, fierce and loving mother has passed away after a battle with cancer, only recently discovered,” her children, True and Lillie Parker, wrote in the statement, which was posted on Alley’s social media accounts.

Alley began her acting career in 1982 with the film “Star Trek II: The Wrath of Khan.” She starred in several other films, and in 1987, she replaced Shelley Long on the show “Cheers.” She won the lead actress Emmy for her role as Rebecca Howe on the show in 1991.

The statement on Alley’s social media mentioned that she was surrounded by her closest family and “fought with great strength.”

The family stated they were grateful for the team of doctors and nurses for taking care of Alley at Moffitt Cancer Center in Tampa, Florida.

“Our mother’s zest and passion for life, her children, grandchildren and her many animals, not to mention her eternal joy of creating, were unparalleled and leave us inspired to live life to the fullest just as she did,” according to the statement.

Alley’s friend and costar, John Travolta, posted a tribute on Instagram, writing, “Kirstie was one of the most special relationships I’ve ever had. I love you, Kirstie. I know we will see each other again.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content